| Literature DB >> 32222473 |
Debasmita Tripathy1, Alice Migazzi1, Federica Costa1, Alessandro Roncador1, Pamela Gatto1, Federica Fusco2, Lucia Boeri3, Diego Albani2, J Leon Juárez-Hernández4, Carlo Musio4, Laura Colombo5, Mario Salmona5, M M Micha Wilhelmus6, Benjamin Drukarch6, Maria Pennuto7, Manuela Basso8.
Abstract
Alzheimer's disease (AD) is the most common cause of dementia. At the pre-symptomatic phase of the disease, the processing of the amyloid precursor protein (APP) produces toxic peptides, called amyloid-β 1-42 (Aβ 1-42). The downstream effects of Aβ 1-42 production are not completely uncovered. Here, we report the involvement of transglutaminase 1 (TG1) in in vitro AD models of neuronal toxicity. TG1 was increased at late stages of the disease in the hippocampus of a mouse model of AD and in primary cortical neurons undergoing stress. Silencing of TGM1 gene was sufficient to prevent Aβ-mediated neuronal death. Conversely, its overexpression enhanced cell death. TGM1 upregulation was mediated at the transcriptional level by an activator protein 1 (AP1) binding site that when mutated halted TGM1 promoter activation. These results indicate that TG1 acts downstream of Aβ-toxicity, and that its stress-dependent increase makes it suitable for pharmacological intervention.Entities:
Keywords: Activator protein 1; Alzheimer's disease; Aβ 1–42 peptides; Neuronal death; Transglutaminase 1
Mesh:
Substances:
Year: 2020 PMID: 32222473 DOI: 10.1016/j.nbd.2020.104849
Source DB: PubMed Journal: Neurobiol Dis ISSN: 0969-9961 Impact factor: 5.996